ZYME Zymeworks Inc
- Stocks
- Healthcare
- NYSE: ZYME
Price (delayed)
$18.05
Market cap
$1.36B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.98
Enterprise value
$1.28B
Relative Growth:
Rel. Growth:
92
Relative Strength:
Rel. Strength:
82
Relative Valuation:
Rel. Valuation:
9
Relative Profitability:
Rel. Profitability:
44
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks' suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of
Highlights
Zymeworks's revenue has soared by 96% YoY and by 32% from the previous quarter
Zymeworks's gross profit has surged by 96% YoY and by 32% QoQ
The company's equity fell by 18% YoY but it rose by 2.9% QoQ
Key stats
What are the main financial stats of ZYME
Market
Valuations
Earnings
Shares outstanding
75.17M
Market cap
$1.36B
Enterprise value
$1.28B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.76
Price to sales (P/S)
11.07
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.39
Revenue
$122.87M
Gross profit
$122.87M
Operating income
-$82.71M
Net income
-$73.68M
EBIT
-$67.42M
EBITDA
-$54.55M
Free cash flow
-$40.46M
Per share
Balance sheet
Liquidity
EPS
-$0.98
EPS diluted
-$0.98
Free cash flow per share
-$0.54
Book value per share
$4.8
Revenue per share
$1.63
TBVPS
$5.23
Total assets
$408.39M
Total liabilities
$73.88M
Debt
$18.68M
Equity
$334.51M
Working capital
$257.63M
Debt to equity
0.06
Current ratio
7.69
Quick ratio
7.38
Net debt/EBITDA
1.46
Margins
Efficiency
Dividend
EBITDA margin
-44.4%
Gross margin
100%
Net margin
-60%
Operating margin
-67.3%
Return on assets
-16.5%
Return on equity
-21.6%
Return on invested capital
-23.3%
Return on capital employed
-18.2%
Return on sales
-54.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZYME stock price
How has the Zymeworks stock price performed over time
Intraday
-0.61%
1 week
-6.86%
1 month
6.55%
1 year
23.12%
YTD
23.29%
QTD
5.68%
Financial performance
How have Zymeworks's revenue and profit performed over time
Revenue
$122.87M
Gross profit
$122.87M
Operating income
-$82.71M
Net income
-$73.68M
Gross margin
100%
Net margin
-60%
Zymeworks's revenue has soared by 96% YoY and by 32% from the previous quarter
Zymeworks's gross profit has surged by 96% YoY and by 32% QoQ
The operating margin has soared by 69% YoY and by 50% from the previous quarter
The company's net margin has surged by 67% YoY and by 51% QoQ
Price vs fundamentals
How does ZYME's price correlate with its fundamentals
Growth
What is Zymeworks's growth rate over time
Valuation
What is Zymeworks stock price valuation
P/E
N/A
P/B
3.76
P/S
11.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.39
ZYME's EPS is up by 35% year-on-year and by 35% since the previous quarter
ZYME's P/B is 57% above its 5-year quarterly average of 2.4 and 45% above its last 4 quarters average of 2.6
The company's equity fell by 18% YoY but it rose by 2.9% QoQ
Zymeworks's revenue has soared by 96% YoY and by 32% from the previous quarter
The stock's price to sales (P/S) is 50% less than its 5-year quarterly average of 22.3 and 6% less than its last 4 quarters average of 11.8
Efficiency
How efficient is Zymeworks business performance
ZYME's ROS has soared by 70% year-on-year and by 52% since the previous quarter
Zymeworks's return on equity has increased by 32% QoQ and by 17% YoY
ZYME's ROIC is up by 31% since the previous quarter and by 22% year-on-year
Zymeworks's ROA has increased by 31% from the previous quarter and by 19% YoY
Dividends
What is ZYME's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ZYME.
Financial health
How did Zymeworks financials performed over time
The quick ratio has surged by 66% since the previous quarter and by 11% year-on-year
The company's current ratio has surged by 63% QoQ and by 10% YoY
The company's debt is 94% lower than its equity
The debt to equity is up by 20% year-on-year
The company's equity fell by 18% YoY but it rose by 2.9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.